The facts
Moderna reported third-quarter 2026 revenue of $1.313 billion, up 29% from $1.016 billion in the same quarter of 2025. [1]
The company reported GAAP net income of $162 million, compared with a $200 million net loss a year earlier. [1]
Moderna raised expected 2026 revenue growth to 15%–25%, from a previous outlook of up to 10%. [1][2]
Moderna said higher international COVID-19 vaccine sales and deliveries under government partnerships primarily drove quarterly revenue growth. [1][2]
Reuters reported quarterly revenue of $1.31 billion exceeded the $885.1 million analyst estimate it cited. [2]
The company said its higher expected year-end cash balance partly reflects $2.6 billion in net proceeds from convertible notes. [1]
Relevant context
The reported earnings and updated guidance are company-specific and do not establish that demand or profitability will continue at the same pace. [1][2]
Still unconfirmed
- The company’s final 2026 revenue and full-year profit remain unknown.
- The results do not establish a broader sector or economy-wide recovery.
Sources
References support the numbered facts above. Source checks: 7 Nov 2026, 03:20 UTC.
The SEC-hosted exhibit is Moderna’s own filing and release; Reuters provides independent coverage and consensus context. The release’s forward-looking guidance is presented as company guidance, not an achieved result.
- Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates
Moderna, Inc. / U.S. Securities and Exchange Commission · Primary source · 6 Nov 2026
Opened SEC-hosted earnings exhibit with the company’s reported revenue, GAAP results, guidance, and explanation of its cash outlook.
- Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas
Reuters, republished by StreetInsider · Reporting · 6 Nov 2026
Opened Reuters report for analyst consensus comparison and independent coverage of the forecast increase; figures retain Reuters’ stated comparison basis.